FibroBiologics Seeks Reverse Split, Massive Share Issuances

Ticker: FBLG · Form: DEF 14A · Filed: Dec 18, 2025 · CIK: 1958777

Sentiment: bearish

Topics: Reverse Stock Split, Share Dilution, Nasdaq Compliance, Special Meeting, Corporate Governance, Warrant Issuance, Biotechnology

Related Tickers: FBLG

TL;DR

**FBLG is doing a reverse split and dumping millions of new shares, signaling desperation and massive dilution ahead – get out now.**

AI Summary

FibroBiologics, Inc. (FBLG) is seeking stockholder approval for a reverse stock split at a ratio between 1-for-5 and 1-for-30, aimed at maintaining Nasdaq listing compliance. The company also seeks approval for the issuance of up to 12,110,203 shares of common stock from a November 18, 2025 Securities Purchase Agreement, up to 4,477,614 shares from November 24, 2025 agreements, and up to 5,227,275 shares from December 14, 2025 agreements. Additionally, 313,433 shares and 365,909 shares are tied to an Engagement Letter with H.C. Wainwright & Co., LLC. These issuances total 22,180,434 shares of common stock, representing significant dilution potential. CEO Pete O'Heeron, through his 2,500 shares of Series C Preferred Stock, controls 32,500,000 votes, or 32.8% of the total votes, and the Board will cast these votes FOR all proposals. The Special Meeting is scheduled for February 20, 2026, virtually.

Why It Matters

This DEF 14A filing reveals FibroBiologics' urgent need to address its stock price, likely to avoid delisting from Nasdaq, through a reverse stock split. For investors, the proposed share issuances totaling 22,180,434 shares represent substantial dilution, potentially impacting per-share value and future stock performance. The strong voting power of CEO Pete O'Heeron, holding 32.8% of total votes via Series C Preferred Stock, ensures the Board's proposals will likely pass, limiting other stockholders' influence. This move could stabilize the company's listing but also signals financial strain and a reliance on dilutive financing, putting FBLG at a competitive disadvantage against better-capitalized biotech firms.

Risk Assessment

Risk Level: high — The proposed reverse stock split, with a ratio up to 1-for-30, indicates a significant risk of delisting from Nasdaq due to low share price. Furthermore, the company is seeking approval for the issuance of 22,180,434 shares of common stock across three separate agreements in November and December 2025, which represents substantial potential dilution to existing shareholders, given 66,519,722 common shares were outstanding as of December 26, 2025.

Analyst Insight

Investors should carefully evaluate the potential for significant dilution from the proposed 22,180,434 share issuances and the implications of a reverse stock split on market perception and liquidity. Consider reducing exposure to FBLG given the high risk of further value erosion and limited shareholder influence due to the CEO's super-voting shares.

Financial Highlights

debt To Equity
0.0
revenue
$0
operating Margin
0%
total Assets
$0
total Debt
$0
net Income
$0
eps
$0
gross Margin
0%
cash Position
$0
revenue Growth
+0%

Key Numbers

Key Players & Entities

FAQ

Why is FibroBiologics proposing a reverse stock split?

FibroBiologics is proposing a reverse stock split at a ratio between 1-for-5 and 1-for-30 to amend its Certificate of Incorporation. This action is typically taken to increase the per-share price of common stock, often to meet minimum bid price requirements for continued listing on exchanges like Nasdaq.

What is the impact of Pete O'Heeron's Series C Preferred Stock on voting?

Pete O'Heeron, as the holder of 2,500 shares of Series C Preferred Stock, controls 32,500,000 votes, which represents 32.8% of the total votes eligible to be cast at the Special Meeting. An irrevocable proxy grants the Board the discretion to vote these shares FOR all proposals, significantly influencing the outcome.

How many new shares is FibroBiologics seeking to issue?

FibroBiologics is seeking approval to issue up to 12,110,203 shares from the November 18 SPA, up to 4,477,614 shares from the November 24 SPA, up to 313,433 shares from the November 24 Engagement Letter, up to 5,227,275 shares from the December SPA, and up to 365,909 shares from the December Engagement Letter, totaling 22,180,434 shares.

When is FibroBiologics' Special Meeting of Stockholders?

The Special Meeting of Stockholders for FibroBiologics is scheduled for Friday, February 20, 2026, at 11:00 a.m. Central Time. It will be held virtually via the Internet at www.virtualshareholdermeeting.com/FBLG2026SM.

What is the record date for voting at the FibroBiologics Special Meeting?

The record date for the FibroBiologics Special Meeting is December 26, 2025. Only stockholders of record at the close of business on this date are entitled to receive notice of and to vote at the Special Meeting.

What are the risks associated with the proposed share issuances for FBLG stockholders?

The proposed issuance of 22,180,434 shares of common stock represents a significant potential for dilution to existing stockholders. With 66,519,722 common shares outstanding as of December 26, 2025, these new shares could substantially decrease the ownership percentage and per-share value for current investors.

Are any of the proposals considered 'routine' for broker voting?

Yes, the amendment to the Certificate of Incorporation to effect the Reverse Stock Split (Proposal 1) and the approval of the adjournment of the Special Meeting (Proposal 5) are considered routine matters. Brokers or nominees may vote on these without specific instructions from beneficial owners.

What is the purpose of the Nasdaq Listing Rule 5635(d) approvals?

The approvals under Nasdaq Listing Rule 5635(d) are required for the issuance of common stock upon the exercise of outstanding warrants from the November 18, November 24, and December 14, 2025 Securities Purchase Agreements and related Engagement Letters. This rule typically applies to transactions that could result in a change of control or significant dilution.

How can FibroBiologics stockholders vote at the Special Meeting?

Stockholders of record can vote at the virtual Special Meeting, by proxy over the telephone, through the Internet at www.virtualshareholdermeeting.com/FBLG2026SM, or by returning a physical proxy card if requested. Beneficial owners should follow instructions from their broker or bank.

What is the Board's recommendation for the proposals?

The Board of Directors urges stockholders to vote FOR each of the five proposals presented at the Special Meeting. This includes the reverse stock split, the three stock issuance proposals, and the adjournment proposal.

Risk Factors

Industry Context

FibroBiologics operates in the biotechnology sector, focusing on regenerative medicine. This industry is characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. Companies often rely on capital raises to fund operations and clinical trials, leading to potential dilution for existing shareholders.

Regulatory Implications

The primary regulatory concern is maintaining compliance with Nasdaq listing rules, specifically the minimum bid price requirement. Failure to do so could lead to delisting. The proposed share issuances also require stockholder approval under Nasdaq rules, highlighting the importance of the upcoming special meeting.

What Investors Should Do

  1. Review the proposed reverse stock split ratio (1-for-5 to 1-for-30) and its potential impact on share price and liquidity.
  2. Assess the dilution impact of the proposed issuance of up to 22,180,434 shares of common stock.
  3. Consider the voting power of CEO Pete O'Heeron (32.8%) and the Board's stated intention to vote FOR all proposals.
  4. Attend the virtual Special Meeting on February 20, 2026, or ensure your proxy is submitted.

Key Dates

Glossary

DEF 14A
A filing with the SEC that provides detailed information about a company's annual shareholders' meeting, including proxy solicitations. (This document outlines the proposals requiring stockholder approval, such as the reverse stock split and share issuances.)
Reverse Stock Split
A corporate action where a company reduces the total number of its outstanding shares by consolidating existing shares into fewer, proportionally more valuable shares. (FibroBiologics is proposing this to meet Nasdaq's minimum bid price requirement.)
Securities Purchase Agreement (SPA)
A contract between a seller and a buyer for the sale of securities, often involving warrants or options to purchase additional shares. (These agreements are the source of a significant number of shares proposed for issuance, leading to potential dilution.)
Engagement Letter
A formal agreement outlining the terms of services between a client and a professional firm, such as an investment bank. (This letter is associated with the potential issuance of shares, contributing to the overall dilution concerns.)
Dilution
The reduction in the ownership percentage of a stock that occurs when a company issues additional shares. (The proposed share issuances will significantly dilute existing shareholders' ownership stakes.)
Series C Preferred Stock
A class of preferred stock with specific rights and privileges, in this case, held by the CEO and carrying significant voting power. (This stock, held by CEO Pete O'Heeron, grants substantial voting control (32.8%) over the proposed resolutions.)

Year-Over-Year Comparison

This DEF 14A filing focuses on an upcoming Special Meeting to address critical Nasdaq listing compliance issues and significant share issuances. Unlike a typical annual report, it does not provide comparative financial data from a prior year. The key metrics highlighted are related to the proposed corporate actions (reverse stock split, share issuances) and voting control, rather than historical financial performance.

Filing Stats: 4,779 words · 19 min read · ~16 pages · Grade level 11.8 · Accepted 2025-12-18 06:37:37

Key Financial Figures

Filing Documents

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 27 OTHER MATTERS 30 Stockholder Proposals for 2026 Annual Meeting 30 Householding of Proxy Materials 30 WHERE YOU CAN FIND MORE INFORMATION 31 Annex A – reverse stock split amendment 32 FIBROBIOLOGICS, INC. 455 E. Medical Center Blvd., Suite 300 Houston, Texas 77598 281-671-5150 PROXY STATEMENT FOR THE SPECIAL MEETING OF STOCKHOLDERS QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Why did I receive a notice regarding the availability of proxy materials on the Internet? Pursuant to rules adopted by the Securities and Exchange Commission, or the SEC, we have elected to provide access to our proxy materials over the Internet. Accordingly, we have sent you a Notice of Internet Availability of Proxy Materials, or the Notice, because the Board of Directors, or the Board, of FibroBiologics, Inc., or FibroBiologics, the Company, we, us or our, is soliciting your proxy to vote at the 2026 Special Meeting of Stockholders, or the Special Meeting, including at any adjournments or postponements of the meeting. All stockholders will have the ability to access the proxy materials on the website referred to in the Notice or request to receive a printed set of the proxy materials. Instructions on how to access the proxy materials over the Internet or to request a printed copy may be found in the Notice. We intend to mail the Notice on or about December 29, 2025 to all stockholders of record entitled to vote at the Special Meeting. Will I receive any other proxy materials by mail? We may send you a proxy card, along with a second Notice, on or after January 9, 2026. How do I attend the Special Meeting? Stockholders as of the record date and/or their authorized representatives are permitted to attend the Special Meeting. The Special Meeting will be held on Friday, February 20, 2026 at 11:00 a.m. Central Time virtually via the Internet at www.virtualshare

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing